• Organon flagged a new post hoc pooled analysis of Phase 3 ADORING 1 and 2 trials for VTAMA in atopic dermatitis.
• Presentation scheduled for July 23, 2026 at the Society for Pediatric Dermatology annual meeting in Minneapolis.
• Analysis targets efficacy and safety across pediatric and adult age subgroups with moderate to severe atopic dermatitis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260707269440) on July 07, 2026, and is solely responsible for the information contained therein.